Log inSign up
Halal screening by industry

Halal Diagnostics & Research stocks

There are 44 listed US companies in Diagnostics & Research: 25 of them (57%) pass AAOIFI screening, 17 are not halal, 1 are doubtful and 1 lack enough data. The industry belongs to the Healthcare sector.

Companies in this industry — screening result

  • Halal25 · 57%
  • Not halal17 · 39%
  • Doubtful1 · 2%
  • Not enough data1 · 2%

44 listed companies in total

Not halal — by reason

17 companies are currently not halal. One company can fail for several reasons; the interest-income test only applies once the debt and cash ratios pass.

  • Cash & investments ≥ 30%11 · 65%
  • Interest-bearing debt ≥ 30% (of market cap)7 · 41%

This is a general observation, not a fatwa. Every company is screened individually — the result is on its own page, with the ratios. Methodology

Largest halal stocks — Diagnostics & Research

The 25 largest by market cap. Open any row for the full stock page — ratios, formula and date.

#CompanyMarket capPriceDebtCashInterest income
1Thermo Fisher Scientific IncTMO$249.61B69021.42.02.2
2Danaher CorporationDHR$158.33B229.0416.62.70.1
3Natera, Inc.NTRA$58.13B393.440.45.22.0
4Agilent Technologies, Inc.A$48.89B172.9710.74.80.9
5Waters CorporationWAT$42.91B436.9522.42.40.6
6IDEXX Laboratories, Inc.IDXX$41.49B560.362.20.50.1
7Illumina, Inc.ILMN$41.23B262.5410.46.00.9
8Mettler-Toledo International, IMTD$32.04B1,622.297.80.2—
9Labcorp Holdings Inc.LH$25.94B317.9529.20.7—
10Guardant Health, Inc.GH$22.15B158.620.414.33.5
11Medpace Holdings, Inc.MEDP$17.56B618.470.04.2—
12Revvity, Inc.RVTY$17.46B152.6426.08.31.1
13Charles River Laboratories InteCRL$14.25B300.1526.71.90.1
14ICON plcICLR$12.97B170.1819.45.30.1
15Qiagen N.V.QGEN$9.53B46.1317.58.43.1
16BillionToOne, Inc.BLLN$4.57B98.122.012.02.5
17Adaptive Biotechnologies CorporADPT$4.10B24.0222.124.63.4
18Veracyte, Inc.VCYT$3.53B43.120.018.52.5
19NeoGenomics, Inc.NEO$2.21B16.6524.19.21.3
20GeneDx Holdings Corp.WGS$2.01B63.619.17.2—
21Myriad Genetics, Inc.MYGN$419.8M3.9817.99.80.2
22Exagen Inc.XGN$203.0M7.7226.126.80.4
23Insight Molecular Diagnostics IIMDX$98.7M3.011.120.7—
24Precipio, Inc.PRPO$39.8M21.3755.614.6—
25Advanced Biomed Inc.ADVB$8.5M3.980.027.8—

Ratios in percent; limits: debt < 30%, cash < 30%, interest income < 5%.

See the whole market in the screener

The public page is a sample. The screener filters by industry, sector and halal status: sort every Diagnostics & Research stock by 40+ metrics (P/E, margins, growth, technicals).

Signing up is free. One minute via Telegram.

Parent sector

All halal stocks in Healthcare

Other industries in Healthcare

Frequently asked questions

Which Diagnostics & Research stocks are halal?
According to our AAOIFI-based screening, 25 of 44 listed Diagnostics & Research companies are halal. The largest by market cap: Thermo Fisher Scientific Inc (TMO), Danaher Corporation (DHR), Natera, Inc. (NTRA), Agilent Technologies, Inc. (A), Waters Corporation (WAT). Each company's ratios are on its stock page.
Why are some Diagnostics & Research companies not halal?
17 companies in this industry are currently not halal. Reasons (one company can fail for several): Cash & investments ≥ 30% — 11; Interest-bearing debt ≥ 30% (of market cap) — 7.
Which sector does Diagnostics & Research belong to?
Diagnostics & Research is an industry within the Healthcare sector. Other industries there with a halal list: Biotechnology, Medical Devices, Medical Instruments & Supplies, Drug Manufacturers - Specialty & Generic, Health Information Services, Medical Care Facilities, Drug Manufacturers - General, Medical Distribution.
Is this a fatwa or investment advice?
No. This is the result of automated screening based on public data. It is neither a fatwa nor an investment recommendation. Consult a scholar or adviser you trust before making decisions.
How often are the results updated?
Screening runs every day: when a new quarterly report comes out, the ratios are recalculated and the status may change. Each stock page shows the date it was checked.

Not a fatwa and not investment advice. Screening is automated from public financial reports and may be wrong or out of date.